提供学术论文选刊润色服务

EXPERT OPINION ON THERAPEUTIC PATENTS 期刊封面

医学

返回期刊列表

Review Cycle Records

EXPERT OPINION ON THERAPEUTIC PATENTS

Taylor & Francis SCIE 非OA

2026新锐 3区2025中科院 2区2025 JCR Q1

查看审稿周期计算与数据来源报告数据问题

100.3平均天数

95中位天数

74最短天数

149最长天数

662025发文量

Paper Review Records

全部论文审稿周期

10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接

79 天

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure–activity relationships and patent coverage

收稿 2026-05-05 录用 2026-07-23 发表 2026-08-05

作者Christian Gege; Gerald Kleymann

作者单位1. Innovative Molecules GmbH

PDF源文件 DOI 网页

140 天

T-type calcium channel blockers: a review of recent advances (2018–2025)

收稿 2026-03-12 录用 2026-07-30 发表 2026-08-04

作者Yasinalli Tamboli; Laurent Ferron; Gerald W. Zamponi

作者单位1. King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs (MNGH); 2. University of Calgary

PDF源文件 DOI 网页

76 天

A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)

收稿 2026-04-28 录用 2026-07-13 发表 2026-07-30

作者Haixiang Qi; Jiayang Wen; Heng Xu

作者单位1. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

PDF源文件 DOI 网页

74 天

A patent perspective of RSK inhibitors to treat cancer (2020-present)

收稿 2026-04-30 录用 2026-07-13 发表 2026-07-29

作者Aviv Preminger; Deborah A. Lannigan

作者单位1. Vanderbilt University; 2. Vanderbilt University Medical Center

PDF源文件 DOI 网页

90 天

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020–present)

收稿 2026-04-03 录用 2026-07-02 发表 2026-07-28

作者Alfie M. Case; Melanie M. Smith; Cole A. Mack; Paul C. Trippier

作者单位1. University of Nebraska Medical Center

PDF源文件 DOI 网页

110 天

Autotaxin inhibitors: an updated patent review (2021-present)

收稿 2026-03-25 录用 2026-07-13 发表 2026-07-18

作者Xiujian Wei; Chengjing Zhao; Zhi Cao; Zehui Tan; Xin Zhai

作者单位1. Shenyang Pharmaceutical University

PDF源文件 DOI 网页

111 天

Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold

收稿 2026-03-18 录用 2026-07-07 发表 2026-07-11

作者Yash Kumar Gaur; Divyanshi Thakur; Shivam Nag; Kalicharan Sharma

作者单位1. ISF College of Pharmacy; 2. Graphic Era Hill University

PDF源文件 DOI 网页

74 天

SLIT2 and ROBO-axis inhibitors for the treatment of cancer: a patent review (2020–2026)

收稿 2026-03-30 录用 2026-06-12 发表 2026-07-07

作者Mahmoud Khatib Al-Ruweidi; Moustafa T. Gabr

作者单位1. Qatar University; 2. Weill Cornell Medicine

PDF源文件 DOI 网页

100 天

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)

收稿 2026-03-14 录用 2026-06-22 发表 2026-07-02

作者Mennatallah Abdallah; Parthiena M. Keddis; Trevina M. Keddis; Dalia S. El-Gamil; Ashraf H. Abadi; Isao Kii; Matthias Engel; Mohammad Abdel-Halim

作者单位1. German University in Cairo; 2. Ahram Canadian University; 3. Shinshu University; 4. Saarland University

PDF源文件 DOI 网页

149 天

A patent review of GPR84 receptor antagonists (2020–present)

收稿 2026-01-21 录用 2026-06-19 发表 2026-06-30

作者Tianyu Mi; Jiawen Yin; Linhai Chen; Fajun Nan

作者单位1. Jiangxi University of Chinese Medicine; 2. Bohai Rim Advanced Research Institute for Drug Discovery; 3. Chinese Academy of Sciences

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求，转成可验证的期刊方案

说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。

客户询问

我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？

CrushSCI回复

可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议: 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
数据库初筛: Environmental Technology & Innovation

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

EXPERT OPINION ON THERAPEUTIC PATENTS

全部论文审稿周期

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure–activity relationships and patent coverage

T-type calcium channel blockers: a review of recent advances (2018–2025)

A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)

A patent perspective of RSK inhibitors to treat cancer (2020-present)

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020–present)

Autotaxin inhibitors: an updated patent review (2021-present)

Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold

SLIT2 and ROBO-axis inhibitors for the treatment of cancer: a patent review (2020–2026)

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)

A patent review of GPR84 receptor antagonists (2020–present)

把投稿要求，转成可验证的期刊方案

联系 CrushSCI

扫码添加微信好友

正在维护

EXPERT OPINION ON THERAPEUTIC PATENTS

全部论文审稿周期

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure–activity relationships and patent coverage

T-type calcium channel blockers: a review of recent advances (2018–2025)

A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)

A patent perspective of RSK inhibitors to treat cancer (2020-present)

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020–present)

Autotaxin inhibitors: an updated patent review (2021-present)

Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold

SLIT2 and ROBO-axis inhibitors for the treatment of cancer: a patent review (2020–2026)

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)

A patent review of GPR84 receptor antagonists (2020–present)

相关榜单与期刊入口